Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR3 | P25089 | 6/20 | 0.36 |
| ▸ | FPR2 | P25090 | 6/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | PRCP | P42785 | 1/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21908286 | 0.98 | HPGD (0.38) | FPR3FPR2SMN1; SMN2HPGDLMNA | |
| SCHEMBL21102868 | 0.98 | HPGD (0.38) | FPR3FPR2SMN1; SMN2HPGDLMNA | |
| SCHEMBL21907929 | 0.93 | GAA (0.31) | — | |
| SCHEMBL21102808 | 0.88 | PRCP (0.31) | FPR3FPR2PRCP | |
| SCHEMBL21102811 | 0.87 | PRCP (0.33) | FPR3FPR2SMN1; SMN2HPGDLMNA | |
| SCHEMBL21102812 | 0.87 | PRCP (0.33) | FPR3FPR2SMN1; SMN2HPGDLMNA | |
| SCHEMBL21103465 | 0.83 | GAA (0.40) | SMN1; SMN2HPGDLMNANAAANPSR1 | |
| SCHEMBL21102810 | 0.81 | GAA (0.30) | — | |
| SCHEMBL21103432 | 0.79 | TSHR (0.32) | — | |
| SCHEMBL21103067 | 0.78 | EPHX2 (0.35) | FPR3FPR2SMN1; SMN2HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10633590-B2 | Liquid crystal composition and liquid crystal display device including the same | DIC CORPORATION (JP) | 2020-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10633590-B2 | Liquid crystal composition and liquid crystal display device including the same | LASP1, UACA, CCDC22 | FPR3 1721/4885FPR2 1620/4885SMN1; SMN2 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.